Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use

Injection drug users who continue to use drugs may not respond to highly active antiretroviral therapy (HAART) as well as other HIV-infected individuals, even after adjusting for a reliable measure of adherence. We therefore compared the virologic response among participants in a population-based HIV/AIDS Drug Treatment Program in British Columbia, Canada, by injection drug use activity. Participants who were HIV infected and naive to antiretroviral therapy and who were prescribed antiretroviral treatment between August 1996 and December 2000 were eligible for this study. They were classified as current, former, or non-injection drug users. The main outcome was having two consecutive HIV-1 RNA levels less than 500 copies/mL. We used logistic regression to adjust for baseline HIV-1 RNA, type of antiretroviral regimen (2 nucleosides + nonnucleoside reverse transcriptase inhibitor versus 2 nucleosides + protease inhibitor), duration of therapy (months), adherence (derived from refill compliance data), and age. A total of 578 participants were first prescribed HAART during the study period. Among them, 78 (13%) were current injection drug users, 96 (17%) were former injection drug users, and 404 (70%) never injected drugs. In the multivariable logistic regression, relative to non-drug users, current injection drug users were significantly less likely to suppress their HIV-1 RNA (adjusted OR [AOR] = 0.30, 95% CI: 0.13–0.67), and former injection drug users were not significantly different from non-drug users (AOR = 0.56, 95% CI: 0.24–1.34). There was a significant interaction between drug use and adherence. In the analyses stratified by drug use, the adherence of former and non-drug users was positively associated with HIV-1 RNA suppression (AOR = 1.33, 95% CI: 1.14–1.55), whereas for current drug users, it was not (AOR = 1.07, 95% CI: 0.87–1.33). Current injection drug users were less likely to achieve HIV-1 RNA suppression compared with non-drug users. Adherence as measured by pharmacy refill compliance was not a reliable measure in this subpopulation.

[1]  B. Yip,et al.  Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up , 2002, AIDS.

[2]  Richard D Moore,et al.  Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic , 2002, AIDS.

[3]  G. Ippolito,et al.  Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. , 2002, AIDS patient care and STDs.

[4]  B. Gazzard,et al.  Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study , 2002, AIDS.

[5]  R. Grant,et al.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Hirsch,et al.  Prevalence and predictive value of intermittent viremia with combination hiv therapy. , 2001, JAMA.

[7]  Richard D Moore,et al.  Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV‐1 Infection , 2001, Journal of acquired immune deficiency syndromes.

[8]  W. Henley,et al.  Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases , 2001, AIDS.

[9]  F. Speranza,et al.  Nevirapine or Efavirenz Combined with Two Nucleoside Reverse Transcriptase Inhibitors Compared to HAART: A Meta-Analysis of Randomized Clinical Trials , 2001, HIV clinical trials.

[10]  R. Hogg,et al.  Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. , 2001, AIDS.

[11]  W. Hauck,et al.  Antiretroviral Use and Pharmacy-Based Measurement of Adherence in Postpartum HIV-Infected Women , 2000, Medical care.

[12]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[13]  R. Hogg,et al.  Adherence to triple therapy and viral load response. , 2000, Journal of acquired immune deficiency syndromes.

[14]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[15]  M. Stein,et al.  Adherence to Antiretroviral Therapy Among HIV-Infected Methadone Patients: Effect of Ongoing Illicit Drug Use* , 2000, The American journal of drug and alcohol abuse.

[16]  Anne M Johnson,et al.  A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. , 1999, Journal of acquired immune deficiency syndromes.

[17]  B. Roca,et al.  Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. , 1999, The Journal of infection.

[18]  R. Hogg,et al.  Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[19]  B. Yip,et al.  Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.

[20]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[21]  M. Wainberg,et al.  Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.

[22]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[23]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[24]  D. Cardo,et al.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. , 1997, The New England journal of medicine.

[25]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[26]  P. Vernazza,et al.  Effect of antiviral treatment on the shedding of HIV‐1 in semen , 1997, AIDS.

[27]  R. Grant,et al.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users , 2002, Journal of General Internal Medicine.

[28]  J. P. Moattia,et al.  Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment , 2022 .